Pulmonx Statistics
Total Valuation
Pulmonx has a market cap or net worth of $121.72 million. The enterprise value is $125.38 million.
| Market Cap | 121.72M |
| Enterprise Value | 125.38M |
Important Dates
The last earnings date was Tuesday, October 27, 2026, after market close.
| Earnings Date | Oct 27, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Pulmonx has 43.55 million shares outstanding. The number of shares has increased by 5.00% in one year.
| Current Share Class | 43.55M |
| Shares Outstanding | 43.55M |
| Shares Change (YoY) | +5.00% |
| Shares Change (QoQ) | +1.67% |
| Owned by Insiders (%) | 5.86% |
| Owned by Institutions (%) | 53.82% |
| Float | 37.61M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.36 |
| Forward PS | 1.25 |
| PB Ratio | 3.26 |
| P/TBV Ratio | 3.87 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.40 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.05, with a Debt / Equity ratio of 1.65.
| Current Ratio | 4.05 |
| Quick Ratio | 3.14 |
| Debt / Equity | 1.65 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -9.39 |
Financial Efficiency
Return on equity (ROE) is -90.31% and return on invested capital (ROIC) is -23.78%.
| Return on Equity (ROE) | -90.31% |
| Return on Assets (ROA) | -19.82% |
| Return on Invested Capital (ROIC) | -23.78% |
| Return on Capital Employed (ROCE) | -44.04% |
| Weighted Average Cost of Capital (WACC) | 5.41% |
| Revenue Per Employee | $299,916 |
| Profits Per Employee | -$143,760 |
| Employee Count | 296 |
| Asset Turnover | 0.71 |
| Inventory Turnover | 1.27 |
Taxes
In the past 12 months, Pulmonx has paid $619,000 in taxes.
| Income Tax | 619,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +43.75% in the last 52 weeks. The beta is 0.17, so Pulmonx's price volatility has been lower than the market average.
| Beta (5Y) | 0.17 |
| 52-Week Price Change | +43.75% |
| 50-Day Moving Average | 2.09 |
| 200-Day Moving Average | 1.68 |
| Relative Strength Index (RSI) | 61.85 |
| Average Volume (20 Days) | 1,193,023 |
Short Selling Information
The latest short interest is 698,644, so 1.60% of the outstanding shares have been sold short.
| Short Interest | 698,644 |
| Short Previous Month | 802,733 |
| Short % of Shares Out | 1.60% |
| Short % of Float | 1.86% |
| Short Ratio (days to cover) | 2.60 |
Income Statement
In the last 12 months, Pulmonx had revenue of $88.78 million and -$42.55 million in losses. Loss per share was -$1.01.
| Revenue | 88.78M |
| Gross Profit | 68.73M |
| Operating Income | -39.41M |
| Pretax Income | -41.93M |
| Net Income | -42.55M |
| EBITDA | -38.62M |
| EBIT | -39.41M |
| Loss Per Share | -$1.01 |
Balance Sheet
The company has $52.69 million in cash and $56.35 million in debt, with a net cash position of -$3.66 million or -$0.08 per share.
| Cash & Cash Equivalents | 52.69M |
| Total Debt | 56.35M |
| Net Cash | -3.66M |
| Net Cash Per Share | -$0.08 |
| Equity (Book Value) | 34.20M |
| Book Value Per Share | 0.79 |
| Working Capital | 63.32M |
Cash Flow
In the last 12 months, operating cash flow was -$30.56 million and capital expenditures -$112,000, giving a free cash flow of -$30.67 million.
| Operating Cash Flow | -30.56M |
| Capital Expenditures | -112,000 |
| Depreciation & Amortization | 997,000 |
| Net Borrowing | 1.68M |
| Free Cash Flow | -30.67M |
| FCF Per Share | -$0.70 |
Margins
Gross margin is 77.42%, with operating and profit margins of -44.39% and -47.93%.
| Gross Margin | 77.42% |
| Operating Margin | -44.39% |
| Pretax Margin | -47.24% |
| Profit Margin | -47.93% |
| EBITDA Margin | -43.50% |
| EBIT Margin | -44.39% |
| FCF Margin | n/a |
Dividends & Yields
Pulmonx does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -5.00% |
| Shareholder Yield | -5.00% |
| Earnings Yield | -36.04% |
| FCF Yield | -25.33% |
Analyst Forecast
The average price target for Pulmonx is $3.70, which is 32.38% higher than the current price. The consensus rating is "Buy".
| Price Target | $3.70 |
| Price Target Difference | 32.38% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | 7.03% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Pulmonx has an Altman Z-Score of -6.16 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -6.16 |
| Piotroski F-Score | 3 |